Navigation Links
ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention

RANCHO CORDOVA, Calif., Dec. 10 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that the Company has introduced a new line of veterinary point-of-care (POC) products under the Vantus brand. Unveiling of the first product, Res-Q60v ePRP, is taking place at this week's 54th Annual Convention of the American Association of Equine Practitioners (AAEP).

The initial product offering, Res-Q60v ePRP will be used for producing equine platelet-rich plasma (PRP) from 60 mL of blood. PRP is being used to treat ligament and tendon injuries in performance horses. The device enables veterinarians to prepare high quality PRP at the point-of-care in less than 15 minutes. The Company plans to introduce Res-Q60v eBMC, another equine product for producing high quality bone marrow concentrate, during calendar 2009. Many performance horses suffer orthopedic injuries and these biological products are emerging as a new means for the treatment to expedite healing of injured ligaments and tendons.

"We have been looking forward to launching the Res-Q60v ePRP at this prestigious equine industry event and commencing commercial sales in the early part of next year. The response among AAEP attendees was favorable and we look forward to participating in the veterinary market as an additional source of revenue for the company," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

"We appreciate the collaborative efforts with the University of California, Davis, School of Veterinary Medicine who consulted with us in our development of this technology specifically for equine applications," Plavan added.

"PRP delivers a high concentration of growth factors to damaged tissue where they stimulate the healing cascade. PRP also has the potential to minimize scarring and decrease the reinjury rate," noted Larry Galuppo, DMV, Associate Professor and Chief of Equine Surgery in the Department of Surgical and Radiological Sciences at the University of California, Davis, School of Veterinary Medicine.

"We are actively defining our marketing strategy to prioritize those opportunities that will enable ThermoGenesis to both meet its financial goals and to expand its leadership position in cell processing. The launch of the Res-Q(TM) technology is a device that addresses an existing and meaningful market opportunity," Plavan noted.

About ThermoGenesis Corp.

ThermoGenesis Corp. ( is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These products include:

-- The BioArchive(R) System, an automated cryogenic device, is used by cord blood stem cell banks in more than 25 countries for cryopreserving and archiving cord blood stem cell units for transplant.

-- AXP(TM) AutoXpress Platform (AXP(TM)) is a proprietary family of automated devices that includes the AXP and the MarrowXpress(TM) and companion sterile blood processing disposable for harvesting stem cells in a closed system. The AXP device is used for the processing of cord blood. GE Healthcare is the exclusive global distribution partner for the AXP cord blood product except for Central and South America, China and Russia/CIS, where ThermoGenesis markets through independent distributors. The MarrowXpress is used for isolating stem cells from bone marrow.

-- The CryoSeal(R) FS System, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community. Asahi Medical is the exclusive distributor for the CryoSeal System in Japan and the Company markets through independent distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The CE-Marked TPD is currently being marketed in Europe by Biomet, Inc., subsidiary Biomet Biologics, Medtronic, Inc. and independent distributors.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2009. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

     ThermoGenesis Corp.
     Web site:
     Contact: Investor Relations
     +1-916-858-5107, or

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
2. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
3. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
4. ThermoGenesis Reports First Quarter 2009 Results
5. ThermoGenesis Announces 10 New BioArchive(R) System Distributors
6. ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
7. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
8. ThermoGenesis Corp. Reports First Quarter 2008 Results
9. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
10. Avon-ISI Launches New Web Site, Toll-free Technical Support Line; Introduces ISI as Fire Market Brand
11. Newport Introduces More Resources for Spanish Speaking Plan Participants
Post Your Comments:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... ... exchange technology and teleradiology services, has added Chris Hafey and Claude Hooton to ... at the Radiological Society of North America (RSNA) 2015 Annual Meeting and continues ...
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... the way that they are handling security in light of the recent terrorist attacks ... in an attempt to stop an attack from reaching U.S. soil. Especially around special ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... how filthy the toilets were," said an inventor from Hillside, N.J. "Many people ... improved seat cover so that individuals will always be protected from germs." , ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 27, 2015 Research and Markets ( ... Intrauterine Devices Market 2015-2019" report to their offering. ... In this report, the author the present scenario and ... 2015-2019. To calculate the market size, the report considers ... products: Hormonal IUDs and copper IUDs. The report forecasts ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
Breaking Medicine Technology: